Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 1 , Pages 17-40 , February 2008

Neonatal hyperglycaemia and abnormal development of the pancreas

  • Hélène Cavé, Dpharm, PhD (Biochemist Involved in the Diagnosis of Genetic Disorders)
  • Michel Polak, MD, PhD (Pediatric Endocrinologist, Professor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +33 1 44 49 48 02; Fax: +33 1 44 38 16 48.

References 

  1. Von Mühlendahl KE, Herkenhoff H. Long-term course of neonatal diabetes. N Engl J Med. 1995;333:704–708
  2. Polak M, Shield J. Neonatal and very-early-onset diabetes mellitus. Semin Neonatol. 2004;9(1):59–65
  3. Ferguson AW, Milner RD. Transient neonatal diabetes mellitus in sibs. Arch Dis Child. 1970;45:80–83
  4. Fösel S. Transient and permanent neonatal diabetes. Eur J Pediatr. 1995;154:944–948
  5. Shield JP, Baum JD. Transient neonatal diabetes and later onset diabetes: a case of inherited insulin resistance. Arch Dis Child. 1995;72:56–57
  6. Metz C, Cave H, Bertrand AM, et al. Neonatal Diabetes Mellitus: chromosomal analysis in transient and permanent cases. J Pediatr. 2002;141:483–489
  7. Temple IK, Gardner RJ, MacKay DJ, Barber JC, Robinson DO, Shield JP. Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes. Diabetes. 2000;49:1359–1366
  8. Shield JP, Temple IK, Sabin M, et al. An assessment of pancreatic endocrine function and insulin sensitivity in patients with transient neonatal diabetes in remission. Arch Dis Child Fetal Neonatal Ed. 2004;89:F341–F343
  9. Marquis E, Le Monnier de Gouville I, Bouvattier C, et al. HLA-DRB1 and DQB1 genotypes in patients with insulin-dependent neonatal diabetes mellitus. A study of 13 cases. Tissue Antigens. 2000;56:217–222
  10. Iafusco D, Stazi MA, Cotichini R, et al. Permanent diabetes mellitus in the first year of life. Diabetologia. 2002 Jun;45:798–804
  11. Temple IK, James RS, Crolla JA, et al. An imprinted gene(s) for diabetes?. Nat Genet. 1995;9:110–112
  12. Christian SL, Rich BH, Loebl C, et al. Significance of genetic testing for paternal uniparental disomy of chromosome 6 in neonatal diabetes mellitus. J Pediatr. 1999;134:42–46
  13. Cave H, Polak M, Drunat S, Denamur E, Czernichow P. Refinement of the 6q chromosomal region implicated in transient neonatal diabetes. Diabetes. 2000;49:108–113
  14. Temple IK, Gardner RJ, Robinson DO, et al. Further evidence for an imprinted gene for neonatal diabetes localized to chromosome 6q22-23. Human Mol Genet. 1996;5:1117–1121
  15. Gardner RJ, Mackay DJ, Mungall AJ, et al. An imprinted locus associated with transient neonatal diabetes mellitus. Hum Mol Genet. 2000;9:589–596
  16. Arima T, Drewell RA, Arney KL, et al. A conserved imprinting control region at the HYMAI/ZAC domain is implicated in transient neonatal diabetes mellitus. Hum Mol Genet. 2001;10:1475–1483
  17. Ma D, Shield JP, Dean W, et al. Impaired glucose homeostasis in transgenic mice expressing the human transient neonatal diabetes mellitus locus, TNDM. J Clin Invest. 2004;114:339–348
  18. Mackay DJ, Boonen SE, Clayton-Smith J, et al. A maternal hypomethylation syndrome presenting as transient neonatal diabetes mellitus. Hum Genet. 2006;120:262–269
  19. Bryan J, Crane A, Vila-Carriles W, et al. Insulin secretagogues, sulfonylurea receptors and K(ATP) channels. Curr Pharm Des. 2005;11(21):2699–2716
  20. Inagaki N, Gonoi T, Clement JP, et al. A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels. Neuron. 1996;16(5):1011–1017
  21. Isomoto S, Kondo C, Yamada M, et al. A novel sulfonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP-sensitive K+ channel. J Biol Chem. 1996;271(40):24321–24324
  22. Inagaki N, Gonoi T, Clement JP, et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science. 1995;270(5239):1166–1170
  23. Gopel SO, Kanno T, Barg S, et al. Regulation of glucagon release in mouse -cells by KATP channels and inactivation of TTX-sensitive Na+ channels. J Physiol. 2000;528(Pt 3):509–520
  24. Gopel SO, Kanno T, Barg S, et al. Patch-clamp characterisation of somatostatin-secreting -cells in intact mouse pancreatic islets. J Physiol. 2000;528(Pt 3):497–507
  25. Gribble FM, Williams L, Simpson AK, et al. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes. 2003;52(5):1147–1154
  26. Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science. 1995;268(5209):423–426
  27. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium channel subunit Kir6.2 gene are associated and permanent neonatal diabetes. N Engl J Med. 2004;350:1838–1849
  28. Winarto A, Miki T, Seino S, et al. Morphological changes in pancreatic islets of KATP channel-deficient mice: the involvement of KATP channels in the survival of insulin cells and the maintenance of islet architecture. Arch Histol Cytol. 2001;64(1):59–67
  29. Miki T, Iwanaga T, Nagashima K, et al. Roles of ATP-sensitive K+ channels in cell survival and differentiation in the endocrine pancreas. Diabetes. 2001;50(Suppl. 1):S48–S51
  30. Seino S, Miki T. Gene targeting approach to clarification of ion channel function: studies of Kir6.x null mice. J Physiol. 2004;554(Pt 2):295–300
  31. Dunn-Meynell AA, Rawson NE, Levin BE. Distribution and phenotype of neurons containing the ATP-sensitive K+ channel in rat brain. Brain Res. 1998;814(1-2):41–54
  32. Yamada K, Inagaki N. Neuroprotection by KATP channels. J Mol Cell Cardiol. 2005;38(6):945–949
  33. Yamada K, Inagaki N. ATP-sensitive K(+) channels in the brain: sensors of hypoxic conditions. News Physiol Sci. 2002;17:127–130
  34. Miki T, Liss B, Minami K, et al. ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nat Neurosci. 2001;4(5):507–512
  35. Deacon RM, Brook RC, Meyer D, et al. Behavioral phenotyping of mice lacking the K ATP channel subunit Kir6.2. Physiol Behav. 2006;87(4):723–733
  36. Gong B, Legault D, Miki T, et al. KATP channels depress force by reducing action potential amplitude in mouse EDL and soleus muscle. Am J Physiol Cell Physiol. 2003;285(6):C1464–C1474
  37. Zingman LV, Hodgson DM, Bast PH, et al. Kir6.2 is required for adaptation to stress. Proc Natl Acad Sci U S A. 2002;99(20):13278–13283
  38. Quayle JM, Nelson MT, Standen NB. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev. 1997;77(4):1165–1232
  39. Koster JC, Marshall BA, Ensorn , et al. Targeted overactivity of beta cell K(ATP) channels induces profound neonatal diabetes. Cell. 2000;100(6):645–654
  40. Gloyn AL, Weedon MN, Owen KR, et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes. 2003;52(2):568–572
  41. Florez JC, Burtt N, de Bakker PI, et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes. 2004;53(5):1360–1368
  42. Tschritter O, Stumvoll M, Machicao F, et al. The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (KIR6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia. Diabetes. 2002;51(9):2854–2860
  43. Vaxillaire M, Populaire C, Busiah K, et al. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes. 2004;53:2719–2722
  44. Massa O, Iafusco D, D'amato E, et al. KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. Hum Mutat. 2005;25(1):22–27
  45. Gloyn AL, Reimann F, Girard C, et al. Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum Mol Genet. 2005;14:925–934
  46. Gloyn AL, Cummines EA, Edehill EL, et al. Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 Gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel. J Clin Endocrinol Metab. 2004;89(8):3932–3935
  47. Proks P, Antcliff JF, Lippiat J, et al. Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci U S A. 2004;101(50):17539–17544
  48. Antcliff JF, Haider S, Proks P, et al. Functional analysis of a structural model of the ATP-binding site of the KATP channel Kir6.2 subunit. Embo J. 2005;24(2):229–239
  49. John SA, Weiss IN, Xiel H, et al. Molecular mechanism for ATP-dependent closure of the K+ channel Kir6.2. J Physiol. 2003;552(Pt 1):23–34
  50. Ribalet B, John SA, Weiss JN. Molecular basis for Kir6.2 channel inhibition by adenine nucleotides. Biophys J. 2003;84(1):266–276
  51. Colombo C, et al. Transient neonatal diabetes mellitus is associated with a recurrent (R201H) KCNJ11 (KIR6.2) mutation. Diabetologia. 2005;48(11):2439–2441
  52. Tammaro P, Proks P, Ashcroft FM. Functional effects of naturally occurring KCNJ11 mutations causing neonatal diabetes on cloned cardiac KATP channels. J Physiol. 2006;571(Pt 1):3–14
  53. Gribble FM, Tucker SJ, Seino S, et al. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes. 1998;47(9):1412–1418
  54. Babenko AP, Polak M, Cavé H, et al. Activating Mutations in ABCC8 gene in neonatal diabetes mellitus. N Engl J Med. 2006;355:456–466
  55. Stanik J, Gasperikova D, Paskova M, et al. Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J Clin Endocrinol Metab. 2007;92(4):1276–1282
  56. Flanagan SE, Patch AM, Mackay DJ, et al. Mutations in KATP channel genes cause transient neonatal diabetes and permanent diabetes in childhood and adulthood. Diabetes. 2007;56:1930–1937
  57. Vaxillaire M, Dechalime A, Busiah K, et al. New ABCC8 mutations in relapsing neonatal diabetes and clinical features. Diabetes. 2007;56:1737–1741
  58. Jonsson J, Carlsson L, Edlund T, Edlund H. Insulin-promoter-factor 1 is required for pancreas development in mice. Nature. 1994;371:606–609
  59. Vaulont S, Vasseur-Cognet M, Kahn A. Glucose regulation of gene transcription. J Biol Chem. 2000;275:31555–31558
  60. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF-1 coding sequence. Nat Genet. 1997;15:106–110
  61. Stoffers DA, Stanojevic V, Habener JF. Insulin Promoter Factor-1 gene mutation linked to early onset type 2 diabetes mellitus directs expression of dominant negative isoprotein. J Clin Invest. 1998;102:232–241
  62. Hoveyda N, Shield JP, Garrett C, et al. Neonatal diabetes mellitus and cerebellar hypoplasia/agenesis: report of a new recessive syndrome. J Med Genet. 1999;36:700–704
  63. Sellick GS, Barker KT, Stolte-Dijkstra I. et al Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat Genet. 2004;36:1301–1305
  64. Ashraf A, Abdullatif H, Hardin W, Moates JM. Unusual case of neonatal diabetes mellitus due to congenital pancreas agenesis. Pediatric diabetes. 2005;6:239–243
  65. Velho G, Froguel P. Genetic, metabolic and clinical characteristics of maturity onset diabetes of the young. Eur J Endocrinol. 1998;138:233–239
  66. Njolstad PR, Sovik O, Cuesta-Munoz A, et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med. 2001;344:1588–1592
  67. Gloyn AL, Ellard S, Shield JP, et al. Complete glucokinase deficiency is not a common cause of permanent neonatal diabetes. Diabetologia. 2002;45:290
  68. Vaxillaire M, Samson C, Cave H, Metz C, Froguel P, Polak M. Glucokinase gene mutations are not a common cause of permanent neonatal diabetes in France. Diabetologia. 2002;45:454–455
  69. Peake JE, McCrossin RB, Byrne G, Shepherd R. X-linked immune dysregulation, neonatal insulin dependent diabetes, and intractable diarrhoea. Arch Dis Child Fetal Neonatal Ed. 1996;74:F195–F199
  70. Roberts J, Searle J. Neonatal diabetes mellitus associated with severe diarrhoea, hyperimmunoglobulin E syndrome, and absence of islets of Langerhans. Pediat Pathol Lab Med. 1995;15:477–483
  71. Satake N, Nakanishi M, Okano M, et al. A Japanese family of X-linked auto-imune enteropathy with haemolytic anaemia and polyendocrinopathy. Eur J Pediat. 1993;152:313–315
  72. Baud O, Goulet O, Canioni D, et al. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. New Eng J Med. 2001;344:1758–1762
  73. Bennett Cl, Christie J, Ramsdell F, et al. The immune dysregulation, poly-endocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27:20–21
  74. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001;27:68–73
  75. Wolcott CD, Rallison ML. Infancy-onset diabetes mellitus and multiple epiphyseal dysplasia. J Pediatr. 1972;80:292–297
  76. Delepine M, Nicolino M, Barrett T, Golamaully M, Lathrop GM, Julier C. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet. 2000;25:406–409
  77. Harding HP, Zhang Y, Bertolotti A, Zeng H, Ron D. Perk is essential for translational regulation and cell survival during unfolded protein response. Mol Cell. 2000;5:897–904
  78. Zhang W, Feng D, Li Y, et al. PERK EIF2AK3 control pancreatic beta cell differentiation and proliferation is required for postnatal glucose homeostasis. Cell Metabolism. 2006;4:491–497
  79. Harding HP, Zeng H, Zhang Y, et al. Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. Mol Cell. 2001;7:1153–1163
  80. Christen HJ, Hanefeld F, Duley JA, Simmonds HA. Distinct neurological syndrome in two brothers with hyperuricaemia. Lancet. 1992;340:1167–1168
  81. Yorifuji T, Matsumura M, Okuno T, et al. Hereditary pancreatic hypoplasia, diabetes mellitus, and congenital heart disease: a new syndrome?. J Med Genet. 1994;31:331–333
  82. Senee V, Chelala C, Duchatelet S, et al. Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism. Nat Genet. 2006;38:682–687
  83. Otonkoski T, Roivainen M, Vaaral O, et al. Neonatal type 1 diabetes associated with maternal echovirus 6 infection: a case report. Diabetologia. 2000;43:1235–1238
  84. Henquin JC. Pathways in beta-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues. Diabetes. 2004;53(Suppl. 3):S48–S58
  85. Gribble FM, Ashcroft FM. Differential sensitivity of beta-cell and extrapancreatic K(ATP) channels to gliclazide. Diabetologia. 1999;42(7):845–848
  86. Gribble FM, Tucker SJ, Ashcroft FM. The interaction of nucleotides with the tolbutamide block of cloned ATP-sensitive K+ channel currents expressed in Xenopus oocytes: a reinterpretation. J Physiol. 1997;504(Pt 1):35–45
  87. Nagashima K, Takahashi A, Ikeda H, et al. Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmachological properties and tissue selectivity. Diabetes Res Clin Pract. 2004;66(Suppl. 1):S75–S78
  88. Zung A, Glaser B, Nimri R, et al. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab. 2004;89(11):5504–5507
  89. Codner E, Flanagan S, Ellard S, et al. High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. Diabetes Care. 2005;28(3):758–759
  90. Sagen JV, Raeder H, Hathout E, et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes. 2004;53:2713–2718
  91. Klupa T, Edghill EL, Nazim L, et al. The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation. Diabetologia. 2005;48(5):1029–1031
  92. Pearson ER, Flechtner I, Njolstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006;355:467–477
  93. Maedler K, Carr RD, Bosco D, et al. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 2005;90(1):501–506
  94. Rustenbeck I, Krautheim A, Jorns A, et al. Beta-cell toxicity of ATP-sensitive K+ channel-blocking insulin secretagogues. Biochem Pharmacol. 2004;67(9):1733–1741
  95. Mitamura R, Kimura H, Murakami Y, Nagaya K, Makita Y, Okuno A. Ultralente insulin treatment of transient neonatal diabetes mellitus. J Pediatr. 1996;128:268–270

PII: S1521-690X(07)00080-2

doi: 10.1016/j.beem.2007.08.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 1 , Pages 17-40 , February 2008

Article Tools

* Image Usage & Resolution